REGENERON PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,027 USD | -0.11% |
|
+2.57% | +16.88% |
Financials (USD)
| Sales 2024 * | 13.82B | Sales 2025 * | 14.94B | Capitalization | 111B |
|---|---|---|---|---|---|
| Net income 2024 * | 3.97B | Net income 2025 * | 4.42B | EV / Sales 2024 * | 7.36 x |
| Net cash position 2024 * | 9.08B | Net cash position 2025 * | 14.86B | EV / Sales 2025 * | 6.43 x |
| P/E ratio 2024 * |
30.4
x | P/E ratio 2025 * |
27.2
x | Employees | 13,677 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 78.42% |
More Fundamentals
* Assessed data
More news
Latest transcript on Regeneron Pharmaceuticals, Inc.
More recommendations
More press releases
More news
| 1 day | -0.11% | ||
| 1 week | +2.57% | ||
| Current month | +4.73% | ||
| 1 month | +5.08% | ||
| 3 months | +6.33% | ||
| 6 months | +17.17% | ||
| Current year | +16.88% |
1 week
992.22
1 030.83
1 month
952.301 030.83
Current year
871.391 030.83
1 year
684.811 030.83
3 years
516.751 030.83
5 years
271.371 030.83
10 years
269.501 030.83
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 64 | 88-01-07 | |
| Chief Executive Officer | 71 | 88-01-07 | |
| Director of Finance/CFO | 53 | 02-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Christine Poon
BRD | Director/Board Member | 71 | 10-11-11 |
| Chief Executive Officer | 71 | 88-01-07 | |
Michael Brown
BRD | Director/Board Member | 83 | 91-05-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 7.27% | 0 M€ | 0.00% | - | |
| 7.08% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-13 | 1,027 | -0.11% | 295,800 |
| 24-06-12 | 1,028 | +1.70% | 453,663 |
| 24-06-11 | 1,011 | +0.88% | 448,231 |
| 24-06-10 | 1,002 | -0.12% | 250,886 |
| 24-06-07 | 1,003 | +0.22% | 250,100 |
Delayed Quote Nasdaq, June 13, 2024 at 04:00 pm EDT
More quotes
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows:
- revenues from product sales (56.6%);
- revenues from collaboration agreements (40.4%): collaboration with Sanofi (58.1% of revenues), Bayer (29.1%) and Roche (12.8%);
- other (3%): primarily revenues from sales of technology licenses and subcontracted research services.
At the end of 2022, the group had a portfolio of approximately 35 products in clinical development.
Calendar
10:30am
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,028
USD
Average target price
1,047
USD
Spread / Average Target
+1.91%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +16.88% | 111B | |
| +17.73% | 123B | |
| -9.04% | 23.63B | |
| +4.40% | 22.58B | |
| -38.15% | 17.61B | |
| -7.75% | 17.6B | |
| -15.36% | 17.26B | |
| +3.42% | 13.55B | |
| +29.63% | 11.34B | |
| +98.87% | 9.94B |
- Stock Market
- Equities
- REGN Stock
